Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

Abstract Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes the lungs of surfactant, leading to prolonged mechanical ventilation and death. The feasibility and safety of surfactant delivery in COVID-19 ARDS patients have not been established. Methods We performed retr...

Full description

Bibliographic Details
Main Authors: Simone Piva, Robert M. DiBlasi, April E. Slee, Alan H. Jobe, Aldo M. Roccaro, Matteo Filippini, Nicola Latronico, Michele Bertoni, John C. Marshall, Michael A. Portman
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Respiratory Research
Subjects:
Covid-19
Acute respiratory distress syndrome
Surfactant replacement therapy
Online Access:https://doi.org/10.1186/s12931-020-01603-w

Internet

https://doi.org/10.1186/s12931-020-01603-w

Similar Items